Keros Therapeutics, Inc. (KROS) Investor Relations Documents

Keros Therapeutics, Inc. (KROS) investor relations documents from the company's IR site: 1 presentation, 14 press releases; latest deck 2026-07-31. Read in-app with summaries. First-party data.

Corporate Presentation August 2026: Keros Therapeutics is a clinical-stage biopharmaceutical company developing rinvatercept (KER-065) to treat neuromuscular diseases like DMD and ALS.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-03Press releaseKeros Therapeutics Reports Second Quarter 2026 Financial Results
2026-07-31PresentationCorporate Presentation August 2026
2026-07-30Press releaseKeros Therapeutics to Receive Development Milestone Payment from Partner Takeda
2026-06-25Press releaseKeros Therapeutics Appoints Anne Prener to its Board of Directors
2026-06-01Press releaseKeros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-14Press releaseKeros Therapeutics Reports Recent First Quarter 2026 Financial Results
2026-03-09Press releaseKeros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scient
2026-03-09Press releaseKeros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
2026-03-04Press releaseKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
2026-02-26Press releaseKeros Therapeutics Appoints Charles Newton to its Board of Directors
2026-02-18Press releaseKeros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Press releaseRead More
Press releaseRead More
Press releaseRead More
Press releaseRead More

KROS overview · KROS earnings · KROS financials · KROS KPIs · KROS ownership · KROS peers · KROS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.